Primary Central Nervous System B-cell Lymphoma
Conditions
Interventions
Case series:High dose Methotrexate (MTX) followed by Etoposide, Cytarabine (EA), stem cell support and temozolomide maintenance therapy
Sponsors
Department of Hematology, Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Diagnosis of Primary Central Nervous System B-cell Lymphoma; 2. Age:18-70; 3. Eastern Cooperative Oncology Group (ECOG) status 0-2 and no chemotherapy contraindications; 4. Estimated survival time >3 months; 5. All patients have to sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Patients combined with any unstable systemic diseases; 3. Hypersensitiveness to any kind of trial regime; 4. Histopathological diagnosis of T cell lymphoma, or Lymphoma cells in bone marrow >=25%.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Grade 3/4 toxicities;Time to progress;Overall survival rate; | — |
Contacts
Public ContactDaobin Zhou
Outcome results
None listed